3 results
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... Crizotinib #ALK #ALKPositive ... #NSCLC #VisualAbstract ... #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival ... #EBM #Honc #Osimertinib ... #NSCLC #Survival ... #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
Progression-free Survival ... #EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM